Navigation Links
Amylin, Lilly Update on FDA Review of BYETTA(R) (exenatide) Injection Monotherapy Submission
Date:12/8/2008

SAN DIEGO and INDIANAPOLIS, Dec. 8 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) is continuing with its review of the regulatory application for use of BYETTA(R) (exenatide) injection as stand-alone therapy (monotherapy) in people with type 2 diabetes who are not achieving acceptable blood sugar control. It is likely that this review will not be complete by the end of 2008, and may extend into 2009.

"Our discussions with the FDA continue to progress and we remain confident in the strength of our regulatory submission," said Orville G. Kolterman, senior vice president of research and development at Amylin Pharmaceuticals. "Importantly, we have not received any request for additional studies. We look forward to working closely with the agency as needed throughout the review process."

The regulatory application for use of BYETTA as monotherapy was submitted in the first quarter of 2008. The FDA is also reviewing several other BYETTA prescribing information updates submitted by the companies, including revision of safety language and conversion of physician labeling to the new standard format.

About BYETTA(R) (exenatide) injection

BYETTA is the first and only FDA-approved incretin mimetic for the treatment of type 2 diabetes. BYETTA exhibits many of the same effects as the human incretin hormone glucagon like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas and brain. BYETTA is approved by the FDA for use by people with type 2 diabetes who are unsuccessful at controlling their blood sugar
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
2. Robert J. Heine, M.D., Ph.D., F.R.C.P. to Join Lilly; Distinguished Diabetes Expert to Lead Diabetes/Endocrine Medical Division
3. Lauren Marangell, M.D. to Join Lilly; Internationally Recognized Expert in Depression Joins as Distinguished Lilly Scholar
4. Genentech/Roches Lucentis and Eli Lillys Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets
5. Lillys CEO Calls for Reform of Nations Drug Safety System
6. Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels
7. Lilly Grant to VA Will Enhance Services for Returning Combat Veterans
8. Lilly Delivers Strong Third-Quarter Results
9. Lilly and MacroGenics Announce Licensing and Collaboration Agreement
10. Eli Lilly and Company Aids California Recovery Effort
11. Eli Lilly and Company Announces 2007 Lilly Reintegration Awards Recipients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... According to Forrester Research, more than 90 percent of ... of information, and thanks to the launching of DCInsurers Agent ... resources on insurance specifically for the state of Colorado can ... step in the growth of our business,” Doug King, owner/agent ... Insurance Resources office. “We recognize that the web is how ...
(Date:8/1/2014)... KY (PRWEB) August 01, 2014 Frontier ... Health Resources and Services Administration’s Advanced Education Nursing ... and will provide direct support to 280 students over ... the AENT Program is to increase the number of ... providers and/or nursing faculty to address the nurse faculty ...
(Date:8/1/2014)... and doctors at the Institute of Bioengineering and ... Cancer Centre Singapore (NCCS) have co-developed the first ... survival outcomes in kidney cancer patients. This breakthrough ... the world,s top urology journal. , According ... "By combining our expertise in molecular diagnostics and ...
(Date:8/1/2014)... St. Christopher's Hospital for Children announced that they ... with Ed Begley Jr, airing later this year 2014, ... St. Christopher's Hospital for Children offers a wide range ... 21 years of age. With over 220 pediatric specialists, ... autism and childhood obesity. , “St. Christopher’s is ...
(Date:8/1/2014)... Utah (PRWEB) August 01, 2014 This ... MonaVie, who completes its 500th week of paying commissions ... the company was founded in January 2005 total $1,405,954,677.06. ... throughout the world. The company pays commissions in 18 ... ILS, JPY, MYR, MXN, NZD, PLN, USD, SGD, KRW, ...
Breaking Medicine News(10 mins):Health News:DCInsurers Agent Doug King Launches a New Website 2Health News:DCInsurers Agent Doug King Launches a New Website 3Health News:Frontier Nursing University Receives $700,000 in Scholarships for Advanced Practice Nursing and Midwifery Students 2Health News:Taking the guesswork out of cancer therapy 2Health News:Taking the guesswork out of cancer therapy 3Health News:Innovations with Ed Begley, Jr. to Feature St. Christopher's Hospital for Children in Upcoming Episode 2Health News:Innovations with Ed Begley, Jr. to Feature St. Christopher's Hospital for Children in Upcoming Episode 3Health News:MonaVie Records 500th Commission Week, Having Paid Out More Than $1.4B in Distributor Commissions 2
... between Elsevier and Diabetes India. The partnership would be ... Diabetes Research & Metabolic Syndrome in June 2006. // ... relationship between diabetes and metabolic syndrome with special reference ... centered approach in treatment of the disorder. ,Diabetes India ...
... breakthrough, scientists have successfully converted human embryonic stem ... future, replacement cartilage could be grown for transplantation ... problems, including sports injuries, new cartilage for people ... reconstructive surgery. , ,The research, to be ...
... scientists have developed a natural or rather biological pacemaker ... heart muscle cells. The newly developed pacemaker can fire ... the heart in a more physiological way., ,Two ... rise to the heart’s normal rhythm by stimulating other ...
... drugs is on the rise in England, accounting for more ... department each year. , ,The findings are based on ... a hospital in South West England. The doctor in charge ... for treatment with special reference to illegal drug abuse., ...
... previous claims new evidence shows the high fat, low carb ... Atkins (or simply the Atkins' diet) could damage the heart., ... and low // carbohydrates directly affected the heart's ability to ... and colleagues from the Cardiac Metabolism Research Group of Oxford ...
... know that heart disease is ranked as the first ... a new, simple test called dobutamine stress echocardiography that ... , ,The study has been conducted among a ... The study participants underwent a certain type of stress ...
Cached Medicine News:Health News:Partnership Between Diabetes India And Elsevier Announced 2Health News:Another Potential Of Stem Cells Discovered: Used For Growing Cartilage 2Health News:Novel Biological Pacemaker Under Construction for Weak Hearts 2Health News:Heart damage a consequence of Atkins’ Die 2Health News:A Simple Test To Detect Heart Disease In Women Can Be Lifesaving 2
(Date:7/31/2014)... July 31, 2014  Sorrento Therapeutics, Inc. (NASDAQ: ... Amar Singh , Chief Business Officer and Executive Vice President. ... on July 30. "Sorrento is deeply saddened and ... Our immediate thoughts go to Amar,s family and friends," said ... Officer. Mr. Singh joined Sorrento in January ...
(Date:7/31/2014)... (NYSE: RMD ) today announced results for its ... 2014.  Revenue for the quarter was $415.2 million, flat compared ... decrease on a constant currency basis). Net income was $87.7 ... ended June 30, 2013. Diluted earnings per share for the ... the quarter ended June 30, 2013.  The ...
(Date:7/31/2014)... July 31, 2014 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... developments for the quarter ended June 30, 2014. ... 30, 2014 Revenue Total revenue for the quarter ended ... for the quarter ended June 30, 2013 primarily due to ... Total revenue for the six months ended ...
Breaking Medicine Technology:Sorrento Announces the Unexpected Death of its Chief Business Officer 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23
The 15D provides high magnification along with an optimized working distance from the cornea. With its 4.11x magnification it is also well suited for disc and macular observation....
... iQ200 Automated Urine Microscopy Analyzer (iQ200) ... (APR) software to classify urine particles ... results. The iQ200 eliminates most technologist ... particle images by automating specimen preparation, ...
... The iQ®200 Sprint Automated Urinalysis System ... fully automated system that performs complete urinalyses ... away. Designed for high volume laboratories or ... The iQ200 Sprint has a processing speed ...
StarClose Clip Applier, (includes), Clip Applier, 6F Exchange Sheath, 6F Dilator, 0.038 50 cm J-Tip Guide Wire ...
Medicine Products: